SCHEMBL5143271

SCHEMBL5143271

COc1[c]c2ccccc2c(Br)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
TUBB1 Q9H4B7 8/20 0.35
TUBB4A P04350 6/20 0.35
TUBB P07437 6/20 0.35
TUBA3C P0DPH7 6/20 0.35
TUBA1B P68363 6/20 0.35
TUBA4A P68366 6/20 0.35
TUBB4B P68371 6/20 0.35
TUBB3 Q13509 6/20 0.35
TUBB2A Q13885 6/20 0.35
TUBB8 Q3ZCM7 6/20 0.35
TUBA3E Q6PEY2 6/20 0.35
TUBA1A Q71U36 6/20 0.35
TUBA1C Q9BQE3 6/20 0.35
TUBB6 Q9BUF5 6/20 0.35
TUBB2B Q9BVA1 6/20 0.35
NQO2 P16083 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL808524 0.79 SYK (0.42) ALDH1A1SMN1; SMN2KDM4EMAPK1TUBB1
SCHEMBL15564056 0.78 TUBB1 (0.32) ALDH1A1SMN1; SMN2KDM4EMAPK1TUBB1
SCHEMBL19732669 0.78 EP300 (0.43) ALDH1A1SMN1; SMN2KDM4EMAPK1TUBB1
SCHEMBL7430263 0.74 MEN1 (0.32) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPGD
SCHEMBL2259297 0.71 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2KDM4EMAPK1TUBB1
SCHEMBL1351941 0.71 HKDC1 (0.35) ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL7675155 0.69 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2KDM4EMAPK1TUBB1
SCHEMBL152741 0.68 KDM4E (0.58) ALDH1A1SMN1; SMN2KDM4EMAPK1NQO2
SCHEMBL1699606 0.67 DYRK1A (0.35) ALDH1A1KDM4E
SCHEMBL8691514 0.66 HPRT1 (0.45) ALDH1A1SMN1; SMN2KDM4EMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285914-B1 Nr1h4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2007-12-19 EP disclosed
EP-1423370-A4 FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
EP-1423111-A4 FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
EP-1423113-A4 NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2007-04-18 EP disclosed
US-20070010562-A1 Nr1h4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2007-01-11 US disclosed
US-7098336-B2 FXR NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2006-08-29 US disclosed
US-20060148876-A1 Nr3b1 nuclear receptor binding 3-substituted pyrazoles PHENEX PHARMACEUTICALS AG (DE) 2006-07-06 US disclosed
EP-1536799-B1 NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS WITH PARTIAL AGONISTIC PROPERTIES PHENEX PHARMACEUTICALS AG (DE) 2006-05-10 EP disclosed
US-7034046-B2 NR1H4 nuclear receptor binding compounds PHENEX PHARMACEUTICALS AG (DE) 2006-04-25 US disclosed
WO-2006002022-A2 COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA IMMUSOL INCORPORATED (US) 2006-01-05 WO disclosed
US-5916899-A SOLID PHASE SYNTHESIS, REACTING PROTECTED AMINO ACID WITH SOLID SUPPORT; FORMING IMINE BY REACTION WITH ALDEHYDE, CYCLIZATION WITH ANHYDRIDE, CLEAVAGE AND DEPROTECTION. TREGA BIOSCIENCES, INC. (US) 1999-06-29 US disclosed
EP-0923734-A1 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 1999-06-23 EP disclosed
US-5874443-A BIOSYNTHESIS TREGA BIOSCIENCES, INC. (US) 1999-02-23 US disclosed
US-5840500-A OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS TREGA BIOSCIENCES, INC. (US) 1998-11-24 US disclosed
EP-0863877-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1998-09-16 EP disclosed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998002741-A9 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES 1998-05-22 WO disclosed
WO-1998002741-A1 QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-01-22 WO disclosed
WO-1997016428-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010562-A1 Nr1h4 nuclear receptor binding compounds NR1H4, NR1H2, NR1H3 ALDH1A1 2359/4885SMN1; SMN2 4595/4885KDM4E 3147/4885
US-20060148876-A1 Nr3b1 nuclear receptor binding 3-substituted pyrazoles NR0B1, NR0B2, NR4A3 ALDH1A1 1188/4885SMN1; SMN2 3775/4885KDM4E 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.